Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. We show 19 historical shares outstanding datapoints in our PRLD shares outstanding history coverage, used to compute PRLD market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing PRLD market cap history over the course of time is important for investors
interested in comparing PRLD's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of PRLD versus a peer is one thing; comparing
PRLD market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like PRLD can fluctuate over the course of history.
With this page we aim to empower investors researching PRLD by allowing them to research the PRLD market cap history. |
Free PRLD Email Alerts:
Video: The Importance of Market Cap
